Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, July 2, 2014, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $147.42 to $14,640,500.00.

Highlighted Stocks Traded by Insiders:

Red Hat (RHT) - FREE Research Report

Cunningham Michael, who is EVP, General Counsel at Red Hat, sold 10,000 shares at $55.36 on July 2, 2014. Following this transaction, the EVP, General Counsel owned 74,873 shares meaning that the stake was reduced by 11.78% with the 10,000-share transaction.

The shares most recently traded at $55.99, up $0.63, or 1.13% since the insider transaction. Historical insider transactions for Red Hat go as follows:

  • 4-Week # shares sold: 48,631
  • 12-Week # shares sold: 68,618
  • 24-Week # shares sold: 82,464

The average volume for Red Hat has been 1.6 million shares per day over the past 30 days. Red Hat has a market cap of $10.6 billion and is part of the technology sector and computer software & services industry. Shares are up 0.16% year-to-date as of the close of trading on Wednesday.

Red Hat, Inc. provides open source software solutions to enterprise customers worldwide. It develops and offers operating system, virtualization, middleware, storage, and cloud technologies. The company has a P/E ratio of 61.0. Currently, there are 15 analysts who rate Red Hat a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RHT - FREE

TheStreet Quant Ratings

rates Red Hat as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full

Red Hat Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Genesco (GCO) - FREE Research Report

Blaufuss William F Jr, who is Director at Genesco, sold 1,083 shares at $82.19 on July 2, 2014. Following this transaction, the Director owned 14,470 shares meaning that the stake was reduced by 6.96% with the 1,083-share transaction.

The shares most recently traded at $82.69, up $0.50, or 0.61% since the insider transaction. Historical insider transactions for Genesco go as follows:

  • 4-Week # shares sold: 46,890
  • 12-Week # shares sold: 48,336
  • 24-Week # shares sold: 117,072

The average volume for Genesco has been 154,200 shares per day over the past 30 days. Genesco has a market cap of $2.0 billion and is part of the services sector and retail industry. Shares are up 12% year-to-date as of the close of trading on Wednesday.

Genesco Inc. is engaged in the retail and wholesale of footwear, apparel, and accessories. The company operates in five segments: Journeys Group, Schuh Group, Lids Sports Group, Johnston & Murphy Group, and Licensed Brands. The company has a P/E ratio of 20.9. Currently, there are 3 analysts who rate Genesco a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GCO - FREE

TheStreet Quant Ratings

rates Genesco as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Genesco Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MedAssets (MDAS) - FREE Research Report

Garner Charles O, who is Chief Financial Officer at MedAssets, sold 3,167 shares at $22.81 on July 2, 2014. Following this transaction, the Chief Financial Officer owned 0 shares meaning that the stake was reduced by 100% with the 3,167-share transaction.

The shares most recently traded at $23.46, up $0.65, or 2.77% since the insider transaction. Historical insider transactions for MedAssets go as follows:

  • 4-Week # shares bought: 8,950
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 8,950
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 8,950
  • 24-Week # shares sold: 61,902

The average volume for MedAssets has been 458,200 shares per day over the past 30 days. MedAssets has a market cap of $1.4 billion and is part of the technology sector and computer software & services industry. Shares are up 17.9% year-to-date as of the close of trading on Wednesday.

MedAssets, Inc., a financial and performance improvement company, provides technology-enabled products and services for hospitals, health systems, and other ancillary healthcare providers in the United States. The company has a P/E ratio of 52.7. Currently, there are 11 analysts who rate MedAssets a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDAS - FREE

TheStreet Quant Ratings

rates MedAssets as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

MedAssets Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null